Physician profile
Asad Jadoon
NPI 1932101771
$1,251.67
in general payments reported to CMS, 2019-2025
17 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $9.82 · 2021: $134 · 2022: $154 · 2023: $224 · 2024: $291 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768 · Education: $41.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.44 |
| Education | $41.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $419.01 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $195.37 | 2019-2024 | |
| Abbott Laboratories | $121.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.38 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $81.75 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.37 | 2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $57.24 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.81 | 2019-2024 | Lifevest |
| Pfizer INC. | $37.30 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $30.32 | 2023-2025 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $20.68 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $19.86 | 2024 | Arcalyst |
| Medtronic, INC. | $19.06 | 2021 | |
| Glaxosmithkline, LLC. | $15.78 | 2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $14.20 | 2024 | Ozempic, Rybelsus |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $9.82 | 2020 | |
| Bard Peripheral Vascular, INC. | $8.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Jadoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.